A retrospective cohort study of severe skin toxicities induced by a BRAF inhibitor-vemurafenib in patients with melanoma
Latest Information Update: 23 Nov 2016
At a glance
- Drugs Vemurafenib (Primary) ; Dabrafenib
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2016 New trial record